U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257458) titled 'Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer' on Nov. 17.
Brief Summary: This study aims to evaluate the utility of combined plasma SHOX2 and PTGER4 gene methylation analysis as a dynamic biomarker for monitoring minimal residual disease (MRD) and predicting recurrence in postoperative non-small cell lung cancer (NSCLC) patients. The primary objective is to determine whether serial methylation assessment can guide personalized adjuvant therapy decisions by identifying high-risk individuals, thereby potentially reducing overtreatment or undertreatment.
Stage I-IV NSCLC patients undergoing su...